Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.40 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.40 |
| ▸ | CPS1 | P31327 | 2/20 | 0.37 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4870381 | 0.86 | MAPK1 (0.48) | SMN1; SMN2HSD11B1KMT2AMAPTMAPK1 | |
| SCHEMBL4870172 | 0.86 | MAPK1 (0.48) | SMN1; SMN2HSD11B1KMT2AMAPTMAPK1 | |
| SCHEMBL4916100 | 0.86 | MAPK1 (0.48) | SMN1; SMN2HSD11B1KMT2AMAPTMAPK1 | |
| SCHEMBL4860899 | 0.81 | RAB9A (0.44) | RAB9ANPC1SMN1; SMN2HSD11B1GAA | |
| SCHEMBL4862053 | 0.80 | USP2 (0.44) | RAB9ANPC1SMN1; SMN2HSD11B1GAA | |
| SCHEMBL4872188 | 0.78 | MAPK1 (0.48) | RAB9ANPC1SMN1; SMN2HSD11B1GAA | |
| SCHEMBL4158564 | 0.77 | KMT2A (0.48) | KMT2AMAPTMAPK1 | |
| SCHEMBL4490813 | 0.77 | HSD11B1 (0.42) | RAB9ANPC1SMN1; SMN2HSD11B1GAA | |
| SCHEMBL3856380 | 0.76 | RAB9A (0.43) | RAB9ANPC1SMN1; SMN2HSD11B1GAA | |
| SCHEMBL4864118 | 0.75 | KMT2A (0.48) | RAB9ANPC1SMN1; SMN2HSD11B1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7351709-B2 | Estrogen receptor ligands | WYETH (US) | 2008-04-01 | — | — | US | disclosed |
| US-20060019961-A1 | Estrogen receptor ligands | WYETH | 2006-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060019961-A1 | Estrogen receptor ligands | GPER1, ESR2, ESR1 | RAB9A 3365/4885NPC1 1178/4885SMN1; SMN2 4822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.